HCG menopauznыy

When ATH: G03GA02

Pharmacological action

HCG menopauznыy, contains LH and FSH. Has FSH and gonadotropin-releasing action. Increases concentration of plasma sex hormone. In women, it causes an increase in the concentration of estrogen in the blood and stimulates the growth of ovarian, therein follicle maturation and ovulation, cause endometrial proliferation. Men stimulates spermatogenesis (by activation of protein synthesis, binding of androgens in the seminiferous tubules and Sertoli cells). It enhances the production of steroid hormones by the gonads. The efficiency is mainly due to the action of FSH.

Testimony

Women: infertility – hypovarianism, amenorrhea (primary or secondary central origin, hypomenstrual syndrome); syndrome Shihena, Chiari syndrome, Frommelya; slowdown of the dominant follicle, superovulation (sets growth of follicles for assisted reproductive techniques, promoting offensive conception); males: infertility – inhibition of spermatogenesis (azoospermia, oligospermatism, due to primary or secondary hypogonadotropic hypogonadism), stimulation of spermatogenesis in combination with hCG preparation.

Contraindications

Hypersensitivity, tumors of the hypothalamic-pituitary region, hyperprolactinemia, adrenal disease and thyroid; for women – persistent increase in ovarian, ovarian cyst (not due to the presence of polycystic ovary syndrome), polycystic ovary syndrome, genital malformations (incompatible with normal pregnancy), hysteromyoma, metrorragija (unknown etiology), estrogen dependent tumors (ovarian cancer, uterine cancer, mammary cancer), primary ovarian failure, pregnancy, lactation; for men – prostate cancer, swelling of the testicles, androgen-dependent tumors.

Side effects

From the digestive system: nausea, vomiting, flatulence, gastralgia. On the part of the endocrine system: mastalgïya, ovarian hyperstimulation syndrome, an increase in the amount of the ovaries, the development of large ovarian cysts, a significant increase in estrogen excretion in the urine, Pain in the lower abdomen; males – gynecomastia. Metabolism: gipovolemiя, blood clots, water and electrolyte disturbances, ascites, gidrotoraks. Allergic reactions: skin rash, hives (antibody formation after prolonged use), fever, arthralgia. Local reactions: edema, pain or itching at the injection site. Other: oligurija, decrease in blood pressure, weight gain, gemoperitoneum, clotting disease, polycyesis.

Dosing and Administration

V / m or s / c, The solution is prepared immediately prior to injection with the supplied solvent. IN 1 ml of the solvent to dissolve the contents 5 ampoules. To stimulate the growth of the dominant follicle in women using 2 Various regimens. The first scheme: daily administration of a dose of 75 IU first 7 days of the cycle in menstruating women. Injections continued until an adequate response, to judge the occurrence of which can be on the daily analysis of the concentration of estrogen and determining the size of the follicles using ultrasound. The maturation of the follicles usually occurs during treatment cycle duration 7-12 days. In the absence of ovarian response on administration a daily dose can be gradually increased to 150 ME. The second scheme: the introduction of a day for 1 Sun. The initial dose is 225-375 IU / day. If adequate stimulation is not reached, the dose may be increased gradually. After the treatment of any of the circuits and with adequate, but not excessive ovarian response, determined on the basis of clinical and biochemical studies, through 24-48 hours after the last administration menotropina, to induce ovulation administered once 5-10 Human thousand IU hCG, increase the content of LH and stimulates the release of a mature egg. In the presence of absence of ovulation and pregnancy treatment may be repeated on one of the above schemes for 2 cycles. On the day of hCG administration and follow-up 2-3 the day the patient is recommended to have sexual intercourse. Upon stimulation “superovulyatsyy” (during assisted reproductive techniques) administration duration may be greater. Application men: hypogonadotropic hypogonadism in the male to stimulate spermatogenesis drug is given, if previous therapy human hCG caused a reaction with no signs of androgen enhance spermatogenesis. In this case, the treatment is continued by introducing 2 Human thousand IU hCG 2 twice a week with injections at menotropina 75 ME 3 times a week. Treatment of this scheme should continue for at least 4 Months, the ineffectiveness of treatment continues, introducing human CG for 2 thousand IU 2 times a week, and 150 ME Menotropins 3 times a week. Status of spermatogenesis should be assessed on a monthly basis, and in the absence of positive results during the subsequent 3 months of treatment should be discontinued. When idiopathic oligospermia normogonadotropic administered weekly 5 Human thousand IU hCG p / or / m, Parallel introduction 75-150 ME Menotropins 3 times a week, during 3 Months. In order to stimulate spermatogenesis – by 1-3 tыs.ME HG 3 once a week to normalize the concentration of testosterone in the blood. Thereafter, for several months 3 times a week – by 75-150 ME Menotropins.

Cautions

Before treatment is necessary to eliminate the wasting syndrome or refractory ovarian, ekstragenital'nye endocrinopathies. The result of treatment can be a multiple pregnancies. In the case of signs of ovarian hyperstimulation (abdominal pain and palpable doctor or determined by ultrasound increased education in the lower abdomen) treatment should be stopped (more likely to develop in women with polycystic ovary syndrome). During the period of treatment required daily ultrasound and hormonal control of developing follicles (ovarian response can be assessed by cervical index). In the case of ovarian hyperstimulation syndrome to enter ovulatory dose of hCG is contraindicated! In the case of pregnancy symptoms excessive hyperstimulation may increase and observed for a long time, It is a threat to the patient's life. Before the appointment of the drug necessary to carry out the appropriate treatment in disorders of the thyroid gland or the adrenal cortex, hyperprolactinemia of various etiologies, tumors of the hypothalamic-pituitary region. During treatment in men with high concentrations in the blood FSH ineffective menotropiny.

Drug Interactions

Do not mix with others. Drugs in the same syringe. When combined with clomiphene reaction increases follicle. In a joint application with GnRH agonists may require increased doses menotropina.